<DOC>
	<DOCNO>NCT00619268</DOCNO>
	<brief_summary>The TORAVA trial design evaluate progression-free rate 48 week combination Torisel® Avastin® give first-line treatment patient metastatic renal cancer . Eligible patient randomly assign , 2:1:1 ratio , either Avastin® + Torisel® , Sutent® IFN+Avastin® .</brief_summary>
	<brief_title>Combination Temsirolimus Bevacizumab Patient With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>This phase II , open label , randomize , parallel group , multicenter study evaluate first-line treatment patient metastatic renal cancer use combination Torisel® administer intravenously 25 mg every week Avastin® administer intravenously 10 mg/kg every 2 week . Two standard arm either Sutent® ( give orally 50 mg daily 4 week , follow 2 week ) combination Avastin® ( administer intravenously 10 mg/kg every 2 week ) Interferon ( IFN , administer subcutaneously 9 MU three time week ) use validate result obtain experimental arm ( randomization eliminate selection bias ) , assess Sutent® efficacy rate representative population Motzer 's trial ( Motzer NEJM 2007 ) . The study design provide head-to-head comparison experimental arm ( Avastin® + Torisel® ) two standard arm ( Sutent® IFN + Avastin® ) . Randomization use tool allocate patient evenly 3 treatment arm ensure proper balance prognostic factor . If progression-free rate observe randomly assign control patient inconsistent historical data , may warn result observe experimental arm view caution . Patients randomly assign either option 2:1:1 ratio ( half less patient standard arm use historical comparators ) , stratify accord inclusion center performance status ( ECOG PS 0 vs. 1 vs. 2 ) . In absence severe toxicity , treatment continue documented progression disease ( RECIST criterion ) . Toxicity evaluate throughout treatment period disappearance stabilization side effect ( ) . In case progression , investigator make his/her treatment decision , provide anti-cancer treatment give patient within frame study report , well result . Response rate assess week 11-12 , 23-24 , 35-36 , 47-48 first year ( correspond 2 cycle Sutent® ) every 3 month afterwards treatment stop , patient death end clinical data collection .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female patient &gt; = 18 year age ; Patients histological cytological evidence metastatic renal cell carcinoma mostly type , except papillary ; No prior systemic treatment ( chemotherapy , immunotherapy , antiangiogenic drug , treatment evaluation ) metastatic renal cancer ; No brain metastases revealed MRI CTscan within 28 day prior randomization . Patients history brain metastasis treat surgery +/ radiation therapy include normal brain MRI ; E.C.O.G performance status = &lt; 2 ; At least one measurable lesion use RECIST criterion ; Blood test renal liver function normal range , 7 day prior study entry , blood serum value follow : Hemoglobin &gt; 8g/dl ; Neutrophil count &gt; 1500*10exp9/L ; Platelets &gt; 100*10exp9/L ; Serum creatinine &lt; 200µmol/L ; Total Bilirubin &lt; 1.5 time upper limit normal ; ALT AST &lt; 2.5 time upper limit normal &lt; 5 ULN patient liver metastasis , PT INR &lt; 1.5 time upper limit normal absence anticoagulant therapy ; Absence proteinuria confirm urinary dipstick test Fertile woman must use effective mean contraception Mandatory affiliation healthy security insurance Signed write informed consent . Patient pure papillary renal cell carcinoma Prior systemic treatment metastatic renal cancer History malignancy , curatively treat insitu carcinoma cervix basal cell carcinoma skin , curatively treat cancer sign recurrence within 5 year prior randomization Evidence brain metastasis computerize tomographic scan MRI 28 day prior randomization . Patients history brain metastasis treat exclusive brain therapy allow participate , even brain MRI normal Significant cardiovascular disease uncontrolled hypertension receive appropriate medication ( &gt; = 160 mm Hg systolic and/or &gt; = 90 mm Hg diastolic ) Hepatic affection like chronic advance hepatitis , liver cirrhosis chronic hepatitis recently treat process treatment immunosuppressive agent , hepatitis autoimmune history autoimmune disease Major surgical procedure , open biopsy , serious non heal wound within 28 day prior randomization Uncontrolled hypercalcemia receive appropriate treatment Uncontrolled hypercholesterolemia hypertriglyceridemia Patient antivitamin K therapy Patient strong CYP3A4 inhibitor Patient severe neuropsychiatric disorder ( comitial crisis ) Patient include another clinical trial , except supportive care trial Pregnant lactate woman ( mandatory negative serum urinary pregnancy test study entry woman childbearing potential )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Temsirolimus</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Metastatic renal cell carcinoma</keyword>
	<keyword>Non-progression</keyword>
</DOC>